ERYTHROPOIESIS-STIMULATING AGENT DOSING AND HEMOGLOBIN TRENDS OVER TIME IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS
Author(s)
Lafeuille MH1, Bailey RA2, Laliberté F1, Senbetta M2, Vekeman F3, McKenzie RS2, Dea K1, Lefebvre P11Groupe d'analyse, Ltée, Montreal, QC, Canada, 2Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 3Analysis Group, Inc., Washington , DC, USA
OBJECTIVES: This study evaluated dosing trends and hemoglobin levels over time in patients with chronic kidney disease (CKD) not on dialysis receiving epoetin alfa (EPO) or darbepoetin alfa (DARB), 2 erythropoiesis-stimulating agents (ESAs). METHODS: An analysis of medical claims between July 2000 and March 2009 from the Ingenix IMPACT database was conducted. Patients ³18 years, newly initiated on ESAs, with ³1 claim for CKD were included. Patients diagnosed with cancer, receiving chemotherapy or dialysis, or receiving both agents were excluded. Average weekly ESA dose, weighted by the treatment duration, was calculated and reported by semester to evaluate trends over time. For the subset of patients with laboratory data, semi-annual mean of baseline and achieved hemoglobin levels were assessed over time. RESULTS: A total of 4,182 ESA-treated patients were identified (EPO 2684; DARB 1,498). Mean age was 64.2 and 63.2 in EPO and DARB groups, respectively, whereas proportion of women was 51% and 55%. The mean weekly dose was relatively stable for both ESAs over time (EPO: mean: 10,652 units; median: 10,623 units; 25th-75th percentiles: 9,872- 11,609 units; DARB: mean: 41 mcg; median: 42 mcg; 25th-75th percentiles: 38-43 mcg); however, a slight decreasing trend was observed in more recent years (2006-2008). Analysis of laboratory results revealed a declining trend in mean baseline hemoglobin over time (10.5 g/dL in 2003S1 vs. 10.1 g/dL in 2008S2) consistent with recent treatment guidelines. A decreasing trend was also observed in mean achieved hemoglobin during the treatment episode (11.9 g/dL in 2003S1 vs. 10.9 g/dL in 2008S2). Furthermore, the proportion of patients with achieved hemoglobin >12g/dL decreased from 41% before April 2006 to 23% in April 2007, after the KDOQI guidelines changed. CONCLUSIONS: This analysis of data from CKD patients not on dialysis reported relatively stable ESA dosing trends and decreasing trend in hemoglobin levels during the study period.
Conference/Value in Health Info
2010-05, ISPOR 2010, Atlanta, GA, USA
Value in Health, Vol. 13, No. 3 (May 2010)
Code
PUK27
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Prescribing Behavior, Treatment Patterns and Guidelines
Disease
Urinary/Kidney Disorders